ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Feinstein Institutes urges areas of focus to improve preventative lung cancer screenings

Approximately 130,000 people will die from lung cancer in 2022, making it the most common cause of cancer death in the United States. A new study recently published in the journal Annals of Internal Medicine, written by The Feinstein Institutes for Medical Research’s Karina Davidson, PhD, reviews preventative lung cancer screening guidelines and outlines hurdles health systems and clinicians still need to overcome to make prevention more effective – including the need for follow-up care.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221014005372/en/

Karina Davidson, PhD, is the director of the Institute of Health System Science at the Feinstein Institutes. (Credit: Feinstein Institutes for Medical Research)

Karina Davidson, PhD, is the director of the Institute of Health System Science at the Feinstein Institutes. (Credit: Feinstein Institutes for Medical Research)

To address the growing lung cancer crisis in 2014, the U.S. Preventative Services Task Force (USPSTF) expanded lung cancer screening guidelines for certain people. In the new paper, “Lessons From Implementation of the United States Preventive Services Task Force Screening for Lung Cancer,” Dr. Davidson, who is the immediate past-chair of the USPSTF, looked at the data comprising the recommendation for low-dose computed tomography (LDCT) screenings for persons aged 55 to 80 years old who had a 30–pack-per-year or greater smoking history. Dr. Davidson wrote and published this article after her tenure with the USPSTF.

“Nearly a quarter of a million Americans will be diagnosed with lung cancer this year, and the prevalence is expected to grow into the future. The best way to curb that prevalence is through prevention,” said Dr. Davidson, director of the Institute of Health System Science at the Feinstein Institutes and the Donald and Barbara Zucker Endowed Professor in Health Outcomes. “By reviewing the USPSTF’s recommendations and current data, we can identify opportunities to implement life-saving preventative screening tactics that will improve the health of our communities.”

The current report analyzed the first one million patients reported to the registry to receive the screenings and found shockingly that 40,000 patients did not have a proper smoking record or order from a doctor to receive the scan. Only 22 percent of those who had their first preventative screening underwent the required one-year follow-up. Race and other patient information are also missing from the registry, making it hard to represent the real world.

Dr. Davidson outlines ways to improve implementation, including clinicians working with their health systems to promote the necessary annual follow-up screenings, which includes examining if dedicated staff and other tools are needed to strengthen follow-up adherence. Additionally, new screening recommendations implemented by the USPSTF in 2021 have increased those eligible, which is especially helpful to those who identify as American Indian, Alaska Native, Black, or Latinx because all of these groups are at a higher risk for lung cancer even when smoking fewer cigarettes.

“Preventive care is the first line of defense against cancer,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. “Dr. Davidson’s thoughtful review of current lung cancer screening guidelines and gaps that should be addressed is timely and important.”

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.56
+0.02 (0.01%)
AAPL  274.61
+0.50 (0.18%)
AMD  209.17
+1.59 (0.77%)
BAC  54.81
-0.52 (-0.94%)
GOOG  307.73
-1.59 (-0.51%)
META  657.15
+9.64 (1.49%)
MSFT  476.39
+1.57 (0.33%)
NVDA  177.72
+1.43 (0.81%)
ORCL  188.65
+3.73 (2.02%)
TSLA  489.88
+14.57 (3.07%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.